|Slideshows|December 5, 2017

13 Contributing Factors to Treatment-Resistant Bipolar Disorder

Author(s)Charles B. Schaffer, MD, Linda C. Schaffer, MD, Jeanne Howe, MA

Several non-biological factors often contribute significantly to treatment resistance.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Keeping Up To Date With Bipolar Disorder

ByMichael E. Henry, MD

June 15th 2026

Dose Lithium Once a Day at Night: An Update

ByDavid N. Osser, MD

June 12th 2026

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

ByJoseph F. Goldberg, MD,Robert M. Post, MD

June 5th 2026

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

ByLeah Kuntz

June 4th 2026

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

ByJessica Walters

May 29th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

13 Contributing Factors to Treatment-Resistant Bipolar Disorder

Related Content

Keeping Up To Date With Bipolar Disorder

Dose Lithium Once a Day at Night: An Update

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

Latest CME

Southern California Psychiatry Conference

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

Zolpidem: Restoring Sleep and Slowing Alzheimer Disease Progression

GABA Deficits and Sleep Disruption in Early Alzheimer Disease

Sleep Changes Across the Lifespan: A Multidimensional Construct

Sleep, Cognition, and the Bidirectional Brain, With Michael Scullin, PhD

What Is Prospective Memory and Why Does It Matter for Patient Care?